
Amicus Therapeutics is a biotechnology business based in the US. Amicus Therapeutics shares (FOLD) are listed on the NASDAQ and all prices are listed in US Dollars. Amicus Therapeutics employs 496 staff and has a trailing 12-month revenue of around $323.3 million.
How to buy Amicus Therapeutics stock
- Choose a stock trading platform. Use our comparison table or choose from our Top Picks below.
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds unto your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – FOLD. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
SoFi Invest
- Trade stocks for $0 and no annual fee
- Start trading with a $0 minimum deposit
- Get up to $1,000 when you fund a new account within 30 days
eToro
- Easy to use platform with low fees
- Social trading allows you to copy popular portfolios
- FINDER EXCLUSIVE: Get $15 when you sign up and deposit $100
Robinhood
- Get free stock upon signup
- Earn 4% interest on uninvested cash with Robinhood Gold
- Get 1% match on contributions to a Robinhood IRA
Amicus Therapeutics stock price (NASDAQ: FOLD)
Use our graph to track the performance of FOLD stocks over time.Amicus Therapeutics shares at a glance
Latest market close | $12.68 |
---|---|
52-week range | $5.91 - $13.62 |
50-day moving average | $12.14 |
200-day moving average | $10.52 |
Wall St. target price | $15.40 |
PE ratio | N/A |
Dividend yield | $0 (0%) |
Earnings per share (TTM) | $-0.97 |
Buy Amicus Therapeutics stocks from these brokerages
Compare special offers, low fees and a wide range of types of investments among top trading platforms.Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
Is it a good time to buy Amicus Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Amicus Therapeutics price performance over time
Historical closes compared with the close of $12.68 from 2023-02-07
1 week (2023-02-01) | -3.65% |
---|---|
1 month (2023-01-06) | 7.64% |
3 months (2022-11-08) | 17.73% |
6 months (2022-08-08) | 1.12% |
1 year (2022-02-04) | N/A |
---|---|
2 years (2021-02-08) | -36.15% |
3 years (2020-02-07) | 23.59% |
5 years (2018-02-08) | 14.875 |
Amicus Therapeutics financials
Revenue TTM | $323.3 million |
---|---|
Gross profit TTM | $271 million |
Return on assets TTM | -17.05% |
Return on equity TTM | -103.69% |
Profit margin | -81.65% |
Book value | $0.47 |
Market capitalisation | $3.7 billion |
TTM: trailing 12 months
Amicus Therapeutics share dividends
We're not expecting Amicus Therapeutics to pay a dividend over the next 12 months.
Amicus Therapeutics share price volatility
Over the last 12 months, Amicus Therapeutics's shares have ranged in value from as little as $5.91 up to $13.62. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Amicus Therapeutics's is 0.8518. This would suggest that Amicus Therapeutics's shares are less volatile than average (for this exchange).
Amicus Therapeutics overview
Amicus Therapeutics, Inc. , a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.
Amicus Therapeutics in the news
Amicus Therapeutics to Present at the SVB Securities Global Biopharma Conference
Amicus Therapeutics to Present at the SVB Securities Global Biopharma Conference
Strength Seen in Syros Pharmaceuticals, Inc. (SYRS): Can Its 5.4% Jump Turn into More Strength?
Frequently asked questions
What percentage of Amicus Therapeutics is owned by insiders or institutions?Currently 0.882% of Amicus Therapeutics shares are held by insiders and 106.078% by institutions. How many people work for Amicus Therapeutics?
Latest data suggests 496 work at Amicus Therapeutics. When does the fiscal year end for Amicus Therapeutics?
Amicus Therapeutics's fiscal year ends in December. Where is Amicus Therapeutics based?
Amicus Therapeutics's address is: 3675 Market Street, Philadelphia, PA, United States, 19104 What is Amicus Therapeutics's ISIN number?
Amicus Therapeutics's international securities identification number is: US03152W1099 What is Amicus Therapeutics's CUSIP number?
Amicus Therapeutics's Committee on Uniform Securities Identification Procedures number is: 03152W109
More guides on Finder
-
How to buy Neuraxis (NRXS) stock when it goes public
Everything we know about the Neuraxis IPO, plus information on how to buy in.
-
How to buy TXO Energy (TXO) stock
Everything we know about the TXO Energy IPO, plus information on how to buy in.
-
How to buy Brera (BREA) stock
Everything we know about the Brera IPO, plus information on how to buy in.
-
How to invest in the S&P 500
What you need to know about investing in the leading indicator for the overall US stock market.
-
How to buy IPO stock
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
-
How to buy Novo Integrated Sciences stock
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
-
How do ETFs work?
Your simple and straightforward guide to ETFs, how they work and the different types available.
-
What is stock lending?
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
-
How to buy SONDORS (SODR) stock when it goes public
Everything we know about the SONDORS IPO, plus information on how to buy in.
-
How to buy Bullfrog AI Holdings (BFRG) stock when it goes public
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
Ask an Expert